卡塔尔单剂与两剂COVID-19疫苗的比较有效性:保护随时间趋同的证据
该研究在卡塔尔开展国家匹配检测阴性病例对照分析,比较单剂与两剂三种疫苗平台对SARS-CoV-2感染和重症COVID-19的保护。单剂对感染的保护逐渐上升并接近两剂水平,对重症的保护在21天内快速超过85%并与两剂相当。
要点
- 单剂BNT162b2对感染的保护从接种后前两周的9.9%升至第3个月的71.5%,接近两剂的74.5%。
- 单剂对重症、危重症或死亡COVID-19的保护在所有三种疫苗中21天内超过85%,与两剂相当。
- 单剂对感染的保护建立较慢,提示第二剂加速免疫应答,抗原剂量可能影响保护建立速度。
核心结论
- 单剂COVID-19疫苗对重症结局提供快速、强效保护,支持供应受限时优先第一剂覆盖。
- 单剂对感染的保护建立较慢,凸显第二剂在加速免疫应答中的作用。
- 抗原剂量似乎影响保护建立的速度。
研究设计与样本
- 在卡塔尔开展国家匹配检测阴性病例对照分析,评估2020年12月1日至2021年12月18日期间的疫苗有效性。
- 单剂分析纳入227,309例病例和4,170,786例对照;两剂分析纳入234,314例病例和6,445,858例对照。
主要发现
- BNT162b2单剂对感染的有效性从接种后前两周的9.9%(95%CI:6.7-13.0%)升至第3个月的71.5%(95%CI:45.5-85.1%),接近两剂基础免疫系列的74.5%(95%CI:72.9-76.0%)。
- mRNA-1273和ChAdOx1 nCoV-19呈现相似趋势,mRNA-1273最早在第2个月达到两剂有效性水平。
- 单剂对重症、危重症或死亡COVID-19的有效性在所有三种疫苗中21天内快速超过85%,与两剂保护密切匹配。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Supply constraints during the coronavirus disease 2019 (COVID-19) pandemic led to vaccination strategies that prioritized first-dose coverage. To evaluate the merit of this approach, this study compared the development of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 following a single dose versus two doses across three widely used vaccine platforms. METHODS: National, matched, test-negative case-control analyses were conducted in Qatar between December 1, 2020, and December 18, 2021, to evaluate vaccine effectiveness. The one-dose analysis included 227,309 cases and 4,170,786 controls; the two-dose analysis included 234,314 cases and 6,445,858 controls. RESULTS: For BNT162b2, single-dose effectiveness against infection increased steadily from 9.9 % (95 % CI: 6.7-13.0 %) in the first two weeks post-vaccination to 71.5 % (95 % CI: 45.5-85.1 %) by month 3, closely approaching the 74.5 % (95 % CI: 72.9-76.0 %) effectiveness observed after the two-dose primary series. Similar trends were observed for mRNA-1273 and ChAdOx1 nCoV-19, with mRNA-1273 reaching two-dose levels of effectiveness as early as month 2. In contrast to the gradual buildup of protection against infection, single-dose effectiveness against severe, critical, or fatal COVID-19 increased rapidly for all three vaccines, exceeding 85 % by day 21 and closely matching the protection achieved after two doses. CONCLUSION: A single COVID-19 vaccine dose provides rapid, strong protection against severe outcomes, supporting first-dose prioritization during supply constraints. The slower development of protection against infection highlights the second dose's role in accelerating the immune response. Antigen dose appears to influence the speed of protection buildup.
引用
- Chemaitelly H, Ayoub HH, Coyle P, et al. Comparative effectiveness of one versus two doses of COVID-19 vaccines in Qatar: Evidence of converging protection over time. Vaccine. 2025. PMID: 40738001. doi:10.1016/j.vaccine.2025.127556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。